

Research and Reviews: Journal of Pharmaceutics & Nanotechnology

Importance of Bioavailability in the Pharmaceutical World

Rita B^{1*}, Akhilesh T²

¹Department of Pharmaceutics, G. Pulla Reddy college of Pharmacy, Osmania University, Hyderabad, India

²Department of Pharmaceutical Analysis, Vathsalya college of Pharmacy, Jawaharlal Nehru Technology University, Hyderabad, India

Commentary Article

Received: 12/04/2015

Revised: 30/05/2015

Accepted: 07/06/2015

*For Correspondence

Department of Pharmaceutics, G. Pulla Reddy college of Pharmacy, Osmania University, Hyderabad, India

Keywords: Bioavailability, Bioequivalence, Dosage form, Parenteral formulations

BIOAVAILABILITY

Bioavailability is characterized as the rate and degree to which the dynamic fixing or dynamic moiety is consumed from a medication item and gets to be accessible at the site of activity. Guaranteeing consistency in gauges of value, viability and wellbeing of pharmaceutical items is the principal obligation of bioavailability studies. For medication items that are not expected to be consumed into the circulatory system, bioavailability ^[1 - 4] may be evaluated by estimations planned to mirror the rate and degree to which the dynamic fixing or dynamic moiety gets to be accessible at the site of activity. Examining from the purpose of sustenance, bioavailability proposes that our digestive framework is capable of extricating nutrients from a product in a shape that can be ingested into the circulation system.

Bioavailability is key from a nourishment perspective as our body gets a greater amount of the available supplements when the supplements are in the fluid structure.

Reasons for Studying Bioavailability

To offer functional data on the potential wellbeing impacts of tainting. It serves to change defaults by utilizing site particular information serves to change proposed cleanup levels and spares time and cash to achieve the acknowledged levels. It serves to organize destinations for ensuing assessment.

Ways to Measure Bioavailability

There are numerous ways that are followed to estimate bioavailability. Site specific analysis can offer essential information that can influence a risk assessment.

Measuring the bioavailability has turned into a vital device to gauge the new plan created by pharmaceutical organization. Famous clinical exploration organizations today direct bioavailability ^[5 - 9] studies to offer different helpful pharmacokinetic data relationship with end, circulation, the impacts of supplements on ingestion of the medication, linearity in the pharmacokinetics of the dynamic moieties, dosage proportionality and may more. Bioavailability data can likewise offer information specifically about the medication substance properties preceding its entrance into the systemic course, enemy

occasion porousness and the effect of presystemic compounds and transporters. When an item is affirmed of having a satisfactory bioavailability then the same item can be chosen for bioequivalence for it to be contrasted and the pioneer drug from a certain administrative.

When the drug is administered orally the bioavailability depends on several factors:

1. Physicochemical properties of the medication and its excipients that focus its disintegration in the intestinal lumen and its retention over the intestinal divider.
2. Decomposition of the medication in the lumen.
3. pH and perfusion of the small digestive system.
4. Surface and time accessible for retention.
5. Competing responses in the lumen (for instance of the medication with nourishment).
6. Hepatic first-pass impact.

Bioavailability can likewise be resolved for other extravascular courses of organization, for example, intramuscular, subcutaneous, rectal, mucosal, sublingual, transdermal and so on. Sublingual and rectal courses are frequently used to sidestep hepatic first-pass impact. Bioavailability of most little atomic weight medications directed i.m. alternately s.c. are perfusion rate-restricted. Huge atoms managed i.m or s.c. enter the blood to a limited extent through the lymphatic pathway^[10 - 13].

At the point when changing the course of organization or the definition of a medication, the measurements must be adjusted as to the separate bioavailability of every course. Bioavailability of a medication managed intravenously is by definition 100%. Bioavailability is less or equivalent to 100% for some other course of organization.

The term outright bioavailability is utilized when the portion of retained medication is identified with its i.v. bioavailability. The term relative bioavailability is utilized to look at two changed extravascular courses of medication organization^[14 - 18]. The term bioequivalence is utilized when two distinctive galenic details of a medication have a comparable bioavailability.

In the gastrointestinal tract the medication can be corrupted by gastric corrosiveness, intestinal layer catalysts, appearance with sustenance constituents or bacterial chemicals. After retention through the intestinal epithelium, medications can be discharged over into the intestinal lumen through dynamic transporters, for example, the P-glycoprotein (PGp). A few medications are further metabolized as an outcome of hepatic first-pass impact, which additionally constrains their assimilation (notwithstanding when intestinal uptake is productive). The sublingual course and to some degree the rectal course can be utilized to by pass this first-pass impact. This impacts the bioavailability of the medication. All medication dosage retained from the gastrointestinal tract is initially conveyed to the liver by the entrance vein. A small amount of the medication can then be metabolized in the liver before it even achieves the systemic course. Thusly the oral bioavailability of the medication is lessened^[19 - 23].

The half-existence of a medication relies on upon its leeway and volume of circulation. The end half-life is thought to be autonomous of the measure of medication in the body^[24 - 27]. Half-life decides the length of the medication impact. It likewise demonstrates whether collection of the medication will happen under a numerous dose regimen and it is crucial to choose the proper dosing interim^[28 - 31].

Hepatic leeway evaluates the loss of medication amid its entry through the liver. Hepatic leeway results from hepatic digestion system and biliary discharge and is an element of the hepatic blood stream, the medication plasma protein tying and the movement of liver catalysts and transporters. Oral bioavailability is identified with the hepatic extraction proportion. The higher the extraction apportion, the higher the hepatic first past impact and bring down the bioavailability^[32 - 38].

Certain patient attributes, for example, age, body weight, comorbidity and comedication can modify the pharmacokinetic parameters of a medication. Populace pharmacokinetics looks to evaluate the degree of the variability of these parameters among a patient populace and to recognize the elements that are in charge of such variability^[39 - 44]. Population pharmacokinetics in the medication advancement procedure aides distinguishes contrasts in medication security and productivity among populace subgroups.

The mean estimations of pharmacokinetic parameters permit the elaboration of the standard measurements regimen of the medication. Variability that is because of influential components prompts measurement adjustment proposed for patient subsets^[45 - 49]. Unexplained variability mirrors the reproducibility of pharmacokinetics. This is critical in light of the fact that the adequacy and wellbeing of a medication may diminish as unexplained variability increments.

Quality Control

Quality control is connected principally to distinctive brands. One medication may be produced by distinctive organizations. These brands have distinctive bioavailability despite the fact that the medication is same. The distinction lies in the assembling procedure.

Molecule size

More noteworthy the size littler is the retention. Size is conversely corresponding to bioavailability. Little molecule size is critical for assimilation of corticosteroids, chloramphenicol and griseofulvin.

Diluents

These are vital when the medication is given in strong structures (tablets, cases, pills). Medication before ingestion must deteriorate and lewd. Crumbling and disintegration may vary with distinctive brands. On the off chance that disintegration time is more, bioavailability will be less and the other way around^[50 - 54]. These are added to Increase mass when dosage is low e.g. digoxin, adds soundness, making medication impervious to natural conditions. Mask offensive taste of medication.

Excipients

Excipients are the dormant substances added to the tablets or pills to expand their mass in light of the fact that occasionally the dose is little.

Diluents

Diluents are dormant substances utilized as a part of instance of fluids. Generally utilized diluents incorporate lactate, lactose, starch, sucrose. Diluents and excipients may influence bioavailability^[55 - 58] of distinctive brands. They may tie with the dynamic rule. Once in a while when the patient is taking one brand for quite a while, abruptly bioavailability^[59 - 64] may change by changing the organization.

Pressure weight

In the event that tablets or pills are all the more firmly bound, the bioavailability is diminished. Dampness substance may act in two ways: (a) In the event that the dampness substance is more, crumbling time is less. (b) At times a few medications when have more dampness, structure bumps in the stomach, which diminishes their absorbance.

Deterioration time

The time in which a strong measurement structure managed orally discharges the dynamic medication for ingestion is called crumbling time.

Clinical Significance

Bioavailability varies with the measurements frames. Medication in fluid structure has more bioavailability than those of solids, while gasses have the most noteworthy bioavailability. This is the reason inward breath is utilized as a part of bronchial asthma ^[65 - 69]. With the same brand, measurements structure made by diverse organizations may vary in bioavailability.

In the event that patient is balanced out on one brand, it ought not to be changed, on the grounds that if the bioavailability is diminished the medication will have less impact or if the bioavailability is expanded, it may prompt danger ^[70 - 75].

Antimicrobials

Against tuberculosis medications must be proceeded for six to nine months. Repeat of illness may happen on changing to brand with less bioavailability, in spite of the fact that side effects vanish following four weeks. Microorganisms might likewise get to be safe.

Anticonvulsants

Anticonvulsant measurement is balanced by beginning from a lower dosage to achieve the state where patient is free from fits. Medications must be proceeded for the entire life. In the event that the brand is changed return of shakings may happen because of diminished bioavailability ^[76 - 81]. Phenytoin is a medication of low helpful file. There exists little contrast in the middle of poisonous and restorative impacts which must be dealt with.

Cardio dynamic medications

Cardio dynamic medications like digoxin have low restorative file. Little changes in plasma levels may prompt harmfulness.

Oral antidiabetic medications

Oral against diabetic medications must be proceeded for the entire life. In the event that bioavailability ^[82 - 86] is expanded, it may prompt hypoglycemia and swooning. Diminished bioavailability may bring about hyperglycemia and diabetic difficulties.

For surveying bioavailability or clinical accessibility of a medication, its rate and degree of ingestion and its first-pass digestion system must be assessed. The clinical reaction of the patient or the measure

of dynamic medication at the objective site of activity at diverse time periods ought to additionally be evaluated. So as to accomplish focused on least level for remedial or clinical impact, the medicinal professional must comprehend different contributing variables that could influence the bioavailability^[87 - 91]. For the researchers, they should likewise be mindful of some vital natural components that impact the definition. There are essentially three variables, which influence bioavailability physiological components, physicochemical elements and pharmacological variables.

Applications for Products Containing Approved Active Substances

Bioequivalence studies

Bioequivalence is obliged if a product is expected to be substituted for a sanction restorative product. Prerequisites for the showing of Bioequivalence may fluctuate with this sort of product.

Oral solutions

If the product is a fluid oral arrangement at time of organization containing the dynamic substance in the same focus and shape as a presently sanction therapeutic item, not containing excipients that may influence gastrointestinal travel or ingestion of the dynamic substance, then a bioequivalence study is not needed. In those situations where an oral arrangement must be tried against a strong measurement structure (e.g., an oral arrangement is planned to be equal to a current tablet), a relative bioavailability study will be obliged unless an exception can be advocated.

Modified release dosage form

Products incorporate deferred discharge items, for example, enteric-covered dose structures and expanded (controlled)-discharge items. Bioequivalence studies for postponed discharge drug items are like those for developed discharge drug items. Extended release items can be cases, tablets, granules, pellets and suspensions. For broadened discharge and postponed discharge drug items, the accompanying studies are prescribed. A solitary measurements, non recreate, fasting study looking at the most elevated quality of the test and reference recorded medication item. A nourishment impact, no imitate study looking at the most noteworthy quality of the test and reference product^[92 - 95].

Oral immediate release products with systemic action

Bioequivalence studies should be performed for all snappy release things expected for systemic action unless, considering most of the going with criteria, the applicant can set up that in vitro are sufficient to ensure Bioequivalence.

Parenteral formulations

The candidate is not needed to present a bioequivalence study if the item is to be managed as an intravenous arrangement containing the dynamic fixing in the same fixation as the as of now approved item.

Bioavailability testing is a method for foreseeing the clinical viability of a medication; the estimation of the bioavailability of a medication in a given measurements structure is direct confirmation of the proficiency with which a measurement structure performs its proposed remedial capacity. The bioavailability of a medication substance figured into a pharmaceutical item is major to the objectives of dose structure configuration and vital for the clinical adequacy of the solution. Consequently, bioavailability testing, which measures the rate and degree of medication retention, is an approach to get proof of the helpful utility of a medication item. Bioavailability determinations are performed by medication producers to guarantee that a given medication item will get the restorative specialists to its site of activity in a satisfactory focus. Bioavailability studies are likewise done to analyze the accessibility of a medication substance from diverse dose frames or from the same measurements structure delivered by distinctive producers ^[96].

One technique for surveying the bioavailability of a medication item is through the exhibit of a clinically critical impact. Notwithstanding, such clinical studies are unpredictable, costly, time intensive and oblige a touchy and quantitative measure of the sought reaction. Further, reaction is regularly very variable, obliging an extensive test populace. Down to earth contemplations, subsequently, block the utilization of this system aside from in introductory phases of improvement while demonstrating the viability of another concoction substance. Measurement of pharmacologic impact is another conceivable approach to survey a drug's bioavailability ^[97,98]. This strategy is in view of the suspicion that a given force of reaction is connected with a specific medication fixation at the site of activity; e.g., variety of mitotic reaction power can be specifically identified with the oral measurement of chlorpromazine. Nonetheless, observing of pharmacologic information is frequently troublesome, exactness and reproducibility are hard to set up, and there are just a set number of pharmacologic impacts (e.g. heart rate, body temperature, glucose levels) that are relevant to this strategy ^[99,100].

REFERENCES

1. Shakeel F, et al. Solubility and Dissolution Improvement of Aceclofenac using Different Nanocarriers. *J Bioequiv Availab* 2009;1: 039-043.
2. Babu B, et al. Pharmacokinetic Evaluation of Metolazone Tablets using Healthy Human Volunteers. *J Bioequiv Availab* 2010;2: 015-017.
3. alma-Aguirre JA, et al. Bioavailability of Two Oral Tablet Formulations of citalopram 20 mg: Single-Dose, Open-Label, Randomized, Two-Period Crossover Comparison in Healthy Mexican Adult Subjects. *J Bioequiv Availab* 2010; 2: 018-022.
4. Bapuji AT, et al. A Bioequivalence Study Comparing Two Formulation of Emtricitabine Capsules. *J Bioequiv Availab* 2010;2: 011-014.
5. Ghnimi S, et al. Fruit Nutraceuticals Seeking Clinical Evidence and Technological Exploitations. *J Bioequiv Availab* 2015;7: e64.
6. Baldo MN, et al. Bioequivalence Evaluation of Two Brands of Ketoprofen. 2015;
7. Gajbhiye KR, et al. Targeted Brain Delivery of Bioactive Molecules Using Nanocarriers. *J Bioequiv Availab* 2015;7: 112-122.
8. Naveed S, et al. Awareness of Jaundice among Pharmacy Undergraduates at, Karachi, Pakistan. *J Bioequiv Availab* 2015;7: 127-130.
9. Khorshid AF, et al. Novel Coated Wires Sensors with Flow- Injection for Potentiometric Determination of Neostigmine in Bulk, Amostigmine and Human Urine. *J Bioequiv Availab* 2015;7: 131-139.
10. Hendawy OM, et al. Effect of Atorvastatin and Vitamin D on Freund's Adjuvant-Induced Rheumatoid Arthritis in Rat. *J Bioequiv Availab* 2015;7: 090-094.
11. Rajeswara Rao P, et al. The Affect of Capmul, Labrafil and Transcutol on Progesterone 100 Mg Soft

- Capsules Bioavailability in Indian Healthy Adult Postmenopausal Female Subjects Under Fasting Conditions. *J Bioequiv Availab* 2015; 7: 095-107.
12. Agatonovic-Kustrin S, et al. Biorelevant Dissolution Studies of Pioglitazone HCL Immediate Release Tablets and the Determination of an In Vitro In Vivo Correlation. *J Bioequiv Availab* 2015;7: 086-089.
 13. Mak WY, et al. Bioequivalence Study of Two IR Metformin Formulations: an Open-Label, Randomised, Two Treatments, Two-Way Crossover Study in Healthy Volunteers. *J Bioequiv Availab* 2015;7: 082-085.
 14. Baldo MN, et al. Bioequivalence Evaluation of Two Brands of Ketoprofen 50 Mg Capsules . 2015;
 15. Ghnimi S, et al. Fruit Nutraceuticals Seeking Clinical Evidence and Technological Exploitations. *J Bioequiv Availab* 2015;7: e64.
 16. Gajbhiye KR, et al. Targeted Brain Delivery of Bioactive Molecules Using Nanocarriers. *J Bioequiv Availab* 2015;7: 112-122.
 17. Azimi M, et al. Investigation on Reaction Diffusion Process Inside a Porous Bio-Catalyst Using DTM. *J Bioequiv Availab* 2015;7: 123-126.
 18. Naveed S, et al. Awareness of Jaundice among Pharmacy Undergraduates at, Karachi, Pakistan. *J Bioequiv Availab* 2015;7: 127-130.
 19. Khorshid AF, et al. Novel Coated Wires Sensors with Flow- Injection for Potentiometric Determination of Neostigmine in Bulk, Amostigmine and Human Urine. *J Bioequiv Availab* 2015;7: 131-139.
 20. Naveed S, et al. Prevalence and Consequences of PHOBIAS, Survey Based Study in Karachi. *J Bioequiv Availab* 2015;07: 140-143.
 21. Mendes GD, et al. Pharmacokinetic Evaluation of Administration of Losartan with Aspirin in Healthy Volunteers. *J Bioequiv Availab* 2015;7: 144-149.
 22. Atkinson HC, et al. A Pharmacokinetic Analysis of a Novel Fixed Dose Oral Combination of Paracetamol and Ibuprofen, with Emphasis on Food Effect. *J Bioequiv Availab* 2015;7: 150-154.
 23. Genel S, et al. Metabolic Syndrome - A Bomb with Delayed Reaction. *J Bioequiv Availab* 2015;7: 155-157.
 24. Ananthula S , et al. Bioavailability and Bioequivalence Issues Associated With Oral Anticancer Drugs and Effect on Drug Market. *J Bioequiv Availab* 2014;6: e56.
 25. Tamayo GM, et al. Bioavailability of Two Tablet Formulations of a Single Dose of Moxifloxacin 400 mg: An Open-Label, Randomized, Two-Period Crossover Comparison in Healthy Mexican Adult Volunteers. *J Bioequiv Availab* 2014; 6: 197-201.
 26. Devineni D, et al. Bioequivalence of Canagliflozin/Metformin Immediate Release Fixed-Dose Combination Tablets Compared with Concomitant Administration of Single Components of Canagliflozin and Metformin in Healthy Fed Participants. *J Bioequiv Availab* 2014;6: 164-173.
 27. Malhotra B, et al. Relative Bioavailability Study of an Abuse-Deterrent Formulation of Extended-Release Oxycodone with Sequestered Naltrexone . 2014;
 28. Mukthinuthalapati MA, et al. Simultaneous Determination of Rosuvastatin and Ezetimibe in pharmaceutical formulations by Stability Indicating Liquid Chromatographic Method. *J Bioequiv Availab* 2014;6: 174-180.
 29. Zhang X, et al. Bioequivalence Study of Two 30 Mg Tolvaptan Tablets Formulations in Healthy Chinese under Fed Condition. *J Bioequiv Availab* 2014;6: 181-185.
 30. Voziyan PA, et al. Reactive Oxygen Species. *J Bioequiv Availab* 2014;6: e57.
 31. Murugesan SMN, et al. Evaluation of Inter-Occasion Variability on Trospium Pharmacokinetics in Healthy Human Subjects using Non-Compartment Methods. *J Bioequiv Availab* 2014;6: 202-205.
 32. Muhammad IN, et al. Pharmacokinetic and Bioequivalence Studies of Oral Cefuroxime Axetil 250 mg Tablets in Healthy Human Subjects. *J Bioequiv Availab* 2014; 6: 149-152.
 33. Butnariu M , et al. Therapeutic Properties of Vegetable. *J Bioequiv Availab* 2014;6: e55
 34. Zhang J, et al. Pharmacokinetics and Bioequivalence Comparison of 600 mg Single-Dose Linezolid Oral Suspension and Tablet Formulation in Healthy Chinese Subjects. *J Bioequiv Availab* 2014; 6: 153-157.

35. Zhao Q, et al. Bioequivalence of Omeprazole Delayed-release Capsules in Healthy Filipino Subjects. *J Bioequiv Availab* 2014;6: 144-149.
36. Bedada SK, et al. Resveratrol Enhances the Bioavailability of Fexofenadine in Healthy Human Male Volunteers: Involvement of P-Glycoprotein Inhibition. *J Bioequiv Availab* 2014;6: 158-163.
37. Butnariu M, et al. Vegetal Metabolomics to Seeds of Galium Aparine. *J Bioequiv Availab* 2013;5: e45.
38. Naveed S , et al. An Overview of Analytical Determination of Captopril in Active Pharmaceutical Ingredients . 2013;
39. Xu W, et al. An In vitro Cell-Based LDL Uptake Model for Screening PCSK 9 Modulators. *J Bioequiv Availab* 2013; 5: 248-252.
40. Zafar F, et al. Need for the Rational Use of Antibacterial in Paediatric Population. *J Bioequiv Availab* 2013;5: 260-263.
41. Nichols AI, et al. An Open-Label Evaluation of the Effect of Coadministering Desvenlafaxine 100 mg on the Pharmacokinetics of Aripiprazole in Healthy Subjects. *J Bioequiv Availab* 2013; 5: 253-259.
42. Glavas-Dodov M, et al. Particulate Carriers for Local Colon Drug Delivery. *J Bioequiv Availab* 2013;5: e25.
43. Basso AMM, et al. Biopharmaceutical and Biosimilar Products in Brazil: From Political To Biotechnological Overview. *J Bioequiv Availab* 2013;5: 060-066.
44. Yazlovitskaya EM , et al. Radioprotectors and Mitigators: Current Status. *J Bioequiv Availab* 2013;5: e26.
45. Nichols A, et al. An Evaluation of the Potential of Cytochrome P 450 3A4-Mediated Drug-Drug Interactions with Desvenlafaxine Use. *J Bioequiv Availab* 2013; 5: 053-059.
46. Araneda C, et al. Single and Multiple Pharmacokinetics of Enrofloxacin and Ciprofloxacin in Pigs. *J Bioequiv Availab* 2013;5: 041-046..
47. Li X, et al. Genetically Modified *Medicago truncatula* Lacking Calcium Oxalate has Increased Calcium Bioavailability and Partially Rescues Vitamin D Receptor Knockout Mice Phenotypes. *J Bioequiv Availab* 2013;5: 047-052.
48. Ayrapetyan SN , et al. Na⁺/K⁺ Pump α 3 Isoform is a Universal Membrane Sensor for Weak Environmental Signals. *J Bioequiv Availab* 2013;5: 031-040.
49. Wagh N, et al. A Bioequivalence Study of Two Finofibrate Tablet Formulations in Indian Healthy Subjects. *J Bioequiv Availab* 2013;5: 016-021.
50. Alice Nichols I, et al. Pharmacokinetics, Pharmacodynamics, and Safety of Desvenlafaxine, a Serotonin-Norepinephrine Reuptake Inhibitor. *J Bioequiv Availab* 2013;5: 022-030.
51. Zhao Q, et al. Relative Bioavailability of a Fixed-Combination Tablet Formulation of Azithromycin and Chloroquine in Healthy Adult Subjects. *J Bioequiv Availab* 2013;5: 001-005.
52. Al-Ghananaem A , et al. Sublingual and Nasal Transmucosal Drug Delivery for Breakthrough Pain: A Frontier in Cancer Therapy. *J Bioequiv Availab* 2013;5: e29.
53. Harahap Y, et al. Bioequivalence of Trimetazidine Modified Release Tablet Formulations Assessed in Indonesian Subjects. *J Bioequiv Availab* 2013;5: 117-120.
54. Sur G, et al. Super-Antigens and Human Pathology: Always an Interesting Topic. *J Bioequiv Availab* 2013;5: 125-128.
55. Ayrapetyan S, et al. Cell Dehydration as a Mechanism of Ketamine Analgesic and Anesthetic Effects. *J Bioequiv Availab* 2013;5: 136-141.
56. Abu-Basha EA, et al. Pharmacokinetics of Gentamicin C 1, C1a, C2 and C2a in Broiler Chickens after IV, IM, SC and Oral Administration. *J Bioequiv Availab* 2013; 5: 129-135.
57. Vassilis K, et al. Transperineal Implementation of Biocompatible Balloon in Patients Treated With Radiotherapy for Prostate Carcinoma: Feasibility and Quality Assurance Study in Terms of Anatomical Stabilization Using Image Registration Techniques. *J Bioequiv Availab* 2013;5: 142-148.
58. Butnariu M, et al. Aspects Relating to Mechanism of the Capsaicinoids Biosynthesis. *J Bioequiv Availab* 2013;5: e32.
59. Yazlovitskaya EM, et al. Mouse Models of Radiosensitivity. *J Bioequiv Availab* 2013;5: e36.
60. Pillay V, et al. Oral Bioavailability and Neuro- Availability vs. α Neuro-Transmittability: A

- Figment of Imagination in the Conundrum of Neuronal Intervention. *J Bioequiv Availab* 2013;5: e34.
61. Zhang A, et al. Statistical Considerations in Biosimilar Assessment Using Biosimilarity Index. *J Bioequiv Availab* 2013;5: 209-214.
 62. Nunez DA, et al. Comparison of Two Formulations of Sodium Divalproate Plasma Concentrations after a Single 500 mg Oral Dose in Healthy Subjects, and Stochastic Sub-analysis of the Individual "Clinical Perceptible" Levels. *J Bioequiv Availab* 2013; 5: 197-200.
 63. Mistry P, et al. Haemolysis Effect Estimation of Doxycycline Hyclate 150 mg Delay Release Tablet in Bio-analysis. 2013;
 64. Suresh Kumar R, et al. Self Nanoemulsifying Drug Delivery System of Olanzapine for Enhanced Oral Bioavailability: In vitro, In vivo Characterisation and In vitro -In vivo Correlation. *J Bioequiv Availab* 2013;5: 201-208.
 65. Mukthinuthalapati MA, et al. A Validated Stability-indicating Liquid Chromatographic Method for Determination of Cabazitaxel-A Novel Microtubule Inhibitor. *J Bioequiv Availab* 2014;6: 134-138.
 66. Jawhari D, et al. Bioequivalence of a New Generic Formulation of Erlotinib Hydrochloride 150 mg Tablets versus Tarceva in Healthy Volunteers under Fasting Conditions. *J Bioequiv Availab* 2014; 6: 119-123.
 67. Vargas M, et al. Bioequivalence Study of Two 50 mg Desvenlafaxine Extended Release Formulations: A Randomized, Single-Dose, Open-Label, Two Periods, Crossover Study. *J Bioequiv Availab* 2014; 6: 115-118.
 68. Naveed S, et al. Degradation Study of Metronidazole in Active and Different Formulation by UV Spectroscopy. *J Bioequiv Availab* 2014;6: 124-127.
 69. Rajeswara Rao P, et al. Intra Subject Variability of Progesterone 200 mg Soft Capsules in Indian Healthy Adult Postmenopausal Female Subjects under Fasting Conditions. *J Bioequiv Availab* 2014; 6: 139-143.
 70. Centuri3n OA , et al. Therapeutic Management in the Idiopathic Ventricular Fibrillation: Is there Still a Place for Pharmacological Treatment? *J Bioequiv Availab* 2014;6: 128-133.
 71. Devi S , et al. Use of Informatics in Identification of Adverse Drug Reactions. *J Bioequiv Availab* 2014;6: e54.
 72. Ananthula S, et al. Bioavailability and Bioequivalence Issues Associated With Oral Anticancer Drugs and Effect on Drug Market. *J Bioequiv Availab*2014;6: e56.
 73. Voziyan PA, et al. Reactive Oxygen Species. *J Bioequiv Availab*2014;6: e57.
 74. Zhang X, et al. Bioequivalence Study of Two 30 Mg Tolvaptan Tablets Formulations in Healthy Chinese under Fed Condition. *J Bioequiv Availab* 2014; 6: 181-185.
 75. Mukthinuthalapati MA, et al. Simultaneous Determination of Rosuvastatin and Ezetimibe in pharmaceutical formulations by Stability Indicating Liquid Chromatographic Method. *J Bioequiv Availab* 2014;6: 174-180.
 76. Shedage A, et al. Comparative Steady State Cross-Over Bioequivalence Study of 35mg Trimetazidine Extended-Release Tablets. *J Bioequiv Availab* 2014; 6: 192-196.
 77. Malhotra B, et al. Relative Bioavailability Study of an Abuse-Deterrent Formulation of Extended-Release Oxycodone with Sequestered Naltrexone. 2014.
 78. Murugesan SMN, et al. Evaluation of Inter-Occasion Variability on Trospium Pharmacokinetics in Healthy Human Subjects using Non-Compartment Methods. *J Bioequiv Availab* 2014;6: 202-205.
 79. Tamayo GM, et al. Bioavailability of Two Tablet Formulations of a Single Dose of Moxifloxacin 400 mg: An Open-Label, Randomized, Two-Period Crossover Comparison in Healthy Mexican Adult Volunteers. *J Bioequiv Availab* 2014; 6: 197-201.
 80. Derakhshandeh K, et al. Oral Bioavailability and Pharmacokinetic Study of Clarithromycin in Different Dosage Forms in Iranian Healthy Volunteers. *J Bioequiv Availab* 2014;6: 206-211.
 81. Yoshiba S, et al. Pharmacokinetics of Laninamivir after a Single Administration of its Prodrug, Laninamivir Octanoate, a Long-Acting Neuraminidase Inhibitor, Using an Easy-to-Use Inhaler in Healthy Volunteers. *J Bioequiv Availab* 2011;3: 001-004.
 82. Nanjwade BK, et al. Development and Characterization of Solid-Lipid Microparticles of Highly

- Insoluble Drug Sirolimus. *J Bioequiv Availab* 2011;3: 011-015.
83. Abib Jr E, et al. Evaluation of the Pharmacokinetic Interaction between Candesartan Cilexetil and Felodipine. *J Bioequiv Availab* 2011;3: 005-010.
 84. Ghosh C, et al. Estimation of Nevirapine from Human Plasma by ESI-LC-MS/MS: a Pharmacokinetic Application. *J Bioequiv Availab* 2011;3: 020-025.
 85. Sunkara G, et al. Assessment of Ethnic Differences in the Pharmacokinetics and Pharmacodynamics of Valsartan. *J Bioequiv Availab* 2010;2: 120-124.
 86. Junior EA, et al. Bioequivalence of Two Oral Contraceptive Drugs Containing Ethinylestradiol and Gestodene in Healthy Female Volunteers. *J Bioequiv Availab* 2010;2: 125-130.
 87. Shafaati A, et al. Rapid and Sensitive Determination Of Montelukast in Human Plasma by High Performance Liquid Chromatographic Method Using Monolithic Column: Application to Pharmacokinetic Studies. *J Bioequiv Availab* 2010;2: 135-138.
 88. Zhang L, et al. Simulation Database System of the Active Ingredients in Compound Decoction of Chinese Medicine. *J Bioequiv Availab* 2010;2: 131-134.
 89. Khattak S, et al. Comparative Bioavailability Assessment of Newly Developed Flurbiprofen Matrix Tablets and Froben SR® Tablets in Healthy Pakistani Volunteers. *J Bioequiv Availab* 2010;2: 139-144.
 90. Shakya R, et al. Comparative Bioavailability of Two Brands of Ofloxacin in Healthy Human Volunteers. *J Bioequiv Availab* 2010;2: 055-058.
 91. Hussain S, et al. Assessment of Bioavailability of Rifampicin as a Component of Anti-tubercular Fixed Dose Combination Drugs Marketed in Pakistan. *J Bioequiv Availab* 2010;2: 067- 071.
 92. Olliaro P, et al. Pharmacokinetics and Comparative Bioavailability of Artesunate and Mefloquine Administered Separately or as a Fixed Combination Product to Healthy Volunteers and Patients with Uncomplicated Plasmodium Falciparum Malaria. *J Bioequiv Availab* 2010;2: 059-066.
 93. Wang LH, et al. Determination of Fragrance Allergens in Essential Oils and Evaluation of their in vitro Permeation from Essential Oil Formulations through Cultured Skin. *J Bioequiv Availab* 2010;2: 072-076.
 94. De Rosa G, et al. New Therapeutic Opportunities from Old Drugs: The Role of Nanotechnology? *J Bioequiv Availab* 2013;5: e30.
 95. Damle B, et al. Bioequivalence of Alprazolam Sublingual Tablet Formulation and Alprazolam Immediate Release Tablet in Healthy Volunteers. *J Bioequiv Availab* 2013;5: 149-153.
 96. Pradeep KV, et al. Importance of ADME and Bioanalysis in the Drug Discovery. *J Bioequiv Availab* 2013;5: e31.
 97. Allen A, et al. The Pharmacokinetics of Fluticasone Furoate and Vilanterol Following Single Inhaled Administration in Combination and Intravenous Administration of Individual Components in Healthy Subjects. *J Bioequiv Availab* 2013;5: 165-173.
 98. Galić J, et al. Study of Local Anaesthetics. Part 203*. Micellization of Heptacainium Chloride Studied By Spectral Methods in Aqueous Solution. *J Bioequiv Availab* 2013; 5: 161-164.
 99. Pohl O, et al. Metabolic Disposition of [14C] Ulipristal Acetate in Healthy Premenopausal Women. *J Bioequiv Availab* 2013;5: 177-184.
 100. Karwa M, et al. Recent Regulatory Amendment in Schedule Y: Impact on Bioequivalence Studies Conducted In India. *J Bioequiv Availab* 2013;5: 174-176.